Literature DB >> 29243164

Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.

Ian R Kleckner1,2, Charles Kamen3, Jennifer S Gewandter3, Nimish A Mohile3, Charles E Heckler3, Eva Culakova3, Chunkit Fung3, Michelle C Janelsins3, Matthew Asare3, Po-Ju Lin3, Pavan S Reddy4, Jeffrey Giguere5, Jeffrey Berenberg6, Shelli R Kesler7, Karen M Mustian3.   

Abstract

PURPOSE: Over half of all cancer patients receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy experience chemotherapy-induced peripheral neuropathy (CIPN), which includes numbness, tingling, pain, cold sensitivity, and motor impairment in the hands and feet. CIPN is a dose-limiting toxicity, potentially increasing mortality. There are no FDA-approved drugs to treat CIPN, and behavioral interventions such as exercise are promising yet understudied. This secondary analysis of our nationwide phase III randomized controlled trial of exercise for fatigue examines (1) effects of exercise on CIPN symptoms, (2) factors that predict CIPN symptoms, and (3) factors that moderate effects of exercise on CIPN symptoms.
METHODS: Cancer patients (N = 355, 56 ± 11 years, 93% female, 79% breast cancer) receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy were randomized to chemotherapy or chemotherapy plus Exercise for Cancer Patients (EXCAP©®). EXCAP is a standardized, individualized, moderate-intensity, home-based, six-week progressive walking and resistance exercise program. Patients reported CIPN symptoms of numbness and tingling and hot/coldness in hands/feet (0-10 scales) pre- and post-intervention. We explored baseline neuropathy, sex, age, body mass index, cancer stage, and cancer type as possible factors associated with CIPN symptoms and exercise effectiveness.
RESULTS: Exercise reduced CIPN symptoms of hot/coldness in hands/feet (-0.46 units, p = 0.045) and numbness and tingling (- 0.42 units, p = 0.061) compared to the control. Exercise reduced CIPN symptoms more for patients who were older (p = 0.086), male (p = 0.028), or had breast cancer (p = 0.076).
CONCLUSIONS: Exercise appears to reduce CIPN symptoms in patients receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy. Clinicians should consider prescribing exercise for these patients. TRIAL REGISTRATION: Clinical Trials.gov , # NCT00924651, http://www.clinicaltrials.gov .

Entities:  

Keywords:  CIPN; Exercise; Neuropathy

Mesh:

Substances:

Year:  2017        PMID: 29243164      PMCID: PMC5823751          DOI: 10.1007/s00520-017-4013-0

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  40 in total

1.  Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry.

Authors:  Floortje Mols; Antoinetta J M Beijers; Gerard Vreugdenhil; Anna Verhulst; Goof Schep; Olga Husson
Journal:  J Cancer Surviv       Date:  2015-04-16       Impact factor: 4.442

2.  Self-efficacy and the stages of exercise behavior change.

Authors:  B H Marcus; V C Selby; R S Niaura; J S Rossi
Journal:  Res Q Exerc Sport       Date:  1992-03       Impact factor: 2.500

Review 3.  Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy.

Authors:  Xiao-Min Wang; Tanya J Lehky; Joanna M Brell; Susan G Dorsey
Journal:  Cytokine       Date:  2012-04-24       Impact factor: 3.861

Review 4.  Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy.

Authors:  Justin G Lees; Preet G S Makker; Ryan S Tonkin; Munawwar Abdulla; Susanna B Park; David Goldstein; Gila Moalem-Taylor
Journal:  Eur J Cancer       Date:  2017-01-16       Impact factor: 9.162

Review 5.  Chemotherapy-induced peripheral neuropathy clinical trials: Review and recommendations.

Authors:  Jennifer S Gewandter; Roy Freeman; Rachel A Kitt; Guido Cavaletti; Lynn R Gauthier; Michael P McDermott; Nimish A Mohile; Supriya G Mohlie; A Gordon Smith; Mohamedtaki A Tejani; Dennis C Turk; Robert H Dworkin
Journal:  Neurology       Date:  2017-07-26       Impact factor: 9.910

Review 6.  Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review.

Authors:  Cloé Brami; Ting Bao; Gary Deng
Journal:  Crit Rev Oncol Hematol       Date:  2015-11-23       Impact factor: 6.312

7.  The validity and utility of the M. D. Anderson Symptom Inventory in patients with breast cancer: evidence from the symptom outcomes and practice patterns data from the eastern cooperative oncology group.

Authors:  Tito R Mendoza; Fengmin Zhao; Charles S Cleeland; Lynne I Wagner; Linda J Patrick-Miller; Michael J Fisch
Journal:  Clin Breast Cancer       Date:  2013-06-28       Impact factor: 3.225

8.  Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy.

Authors:  F Streckmann; S Kneis; J A Leifert; F T Baumann; M Kleber; G Ihorst; L Herich; V Grüssinger; A Gollhofer; H Bertz
Journal:  Ann Oncol       Date:  2014-02       Impact factor: 32.976

9.  Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials.

Authors:  David Hui; Isabella Glitza; Gary Chisholm; Sriram Yennu; Eduardo Bruera
Journal:  Cancer       Date:  2012-11-06       Impact factor: 6.860

10.  Evidence for a Large-Scale Brain System Supporting Allostasis and Interoception in Humans.

Authors:  Ian R Kleckner; Jiahe Zhang; Alexandra Touroutoglou; Lorena Chanes; Chenjie Xia; W Kyle Simmons; Karen S Quigley; Bradford C Dickerson; Lisa Feldman Barrett
Journal:  Nat Hum Behav       Date:  2017-04-24
View more
  75 in total

Review 1.  Physical Activity, Exercise and Breast Cancer - What Is the Evidence for Rehabilitation, Aftercare, and Survival? A Review.

Authors:  Petra Wirtz; Freerk T Baumann
Journal:  Breast Care (Basel)       Date:  2018-04-11       Impact factor: 2.860

Review 2.  Peripheral neuropathy in children and adolescents treated for cancer.

Authors:  Kari L Bjornard; Laura S Gilchrist; Hiroto Inaba; Barthelemy Diouf; Marilyn J Hockenberry; Nina S Kadan-Lottick; Daniel C Bowers; M Eileen Dolan; Nicole J Ullrich; William E Evans; Kirsten K Ness
Journal:  Lancet Child Adolesc Health       Date:  2018-09-01

3.  Letter to the editor-comments on Kleckner et al. (2018) "Effects of exercise during chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial".

Authors:  J K Vallance; K A Bolam
Journal:  Support Care Cancer       Date:  2018-07-22       Impact factor: 3.603

4.  Chemotherapy-induced peripheral neuropathy-more high-quality research is needed.

Authors:  Richard Crevenna; Mohammad Keilani
Journal:  Support Care Cancer       Date:  2018-07-25       Impact factor: 3.603

5.  The associations between physical activity, neuropathy symptoms and health-related quality of life among gynecologic cancer survivors.

Authors:  Lauren Thomaier; Patricia Jewett; Katherine Brown; Rachael Gotlieb; Deanna Teoh; Anne H Blaes; Peter Argenta; Rachel I Vogel
Journal:  Gynecol Oncol       Date:  2020-06-01       Impact factor: 5.482

6.  Evaluation of the effects of sensorimotor exercise on physical and psychological parameters in breast cancer patients undergoing neurotoxic chemotherapy.

Authors:  Paul Lennart Vollmers; Christoph Mundhenke; Nicolai Maass; Dirk Bauerschlag; Stefan Kratzenstein; Christoph Röcken; Thorsten Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  2018-06-25       Impact factor: 4.553

Review 7.  A systematic review of behavioural and exercise interventions for the prevention and management of chemotherapy-induced peripheral neuropathy symptoms.

Authors:  Mary Anne Lagmay Tanay; Jo Armes; Rona Moss-Morris; Anne Marie Rafferty; Glenn Robert
Journal:  J Cancer Surviv       Date:  2021-03-12       Impact factor: 4.442

8.  Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial.

Authors:  Charles Loprinzi; Jennifer G Le-Rademacher; Neil Majithia; Ryan P McMurray; Carrie R O'Neill; Markus A Bendel; Andreas Beutler; Daniel H Lachance; Andrea Cheville; David M Strick; David F Black; Jon C Tilburt; Thomas J Smith
Journal:  Support Care Cancer       Date:  2019-06-17       Impact factor: 3.603

9.  Physical interventions for patients suffering from chemotherapy-induced polyneuropathy.

Authors:  Richard Crevenna; Fredrick D Ashbury
Journal:  Support Care Cancer       Date:  2018-01-27       Impact factor: 3.603

Review 10.  Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment.

Authors:  Nathan P Staff; Guido Cavaletti; Badrul Islam; Maryam Lustberg; Dimitri Psimaras; Stefano Tamburin
Journal:  J Peripher Nerv Syst       Date:  2019-10       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.